What is the current stock price of Aptose Biosciences Inc. (APTO)?

As of the latest market data, Aptose Biosciences Inc. (APTO) is trading at $1.71. The stock has seen a gain of 100.00% today.

Does Aptose Biosciences Inc. (APTO) pay a dividend?

Based on current data, Aptose Biosciences Inc. does not have a confirmed active dividend policy.

What is the market cap of Aptose Biosciences Inc.?

The current market capitalization of Aptose Biosciences Inc. (APTO) is approximately unavailable.

APTO

Aptose Biosciences Inc.·Healthcare

1.71

100.000%(+1.71)

Close Price

2.17

26.901%(+0.46)

After Hours

Last Updated: — ET

52W L: $1.1052W H: $43.19

APTO NEWS

globenewswire.com

May 13

Aptose Reports First Quarter 2026 Results

SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. “Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML) continues to deliver robust safety and response data, and we're pleased that an update of our TUS+VEN+AZA triplet clinical data has been selected for an oral presentation at the upcoming EHA2026 Congress in June,” said William G.

defenseworld.net

Mar 31

Aptose Biosciences (TSE:APS) Stock Passes Above 50-Day Moving Average – Time to Sell?

Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO)'s share price passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of C$2.21 and traded as high as C$2.25. Aptose Biosciences shares last traded at C$2.25, with a volume of 3,066 shares changing hands. Aptose

Company Profile

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

1992-03-16

Beta

1.13

Websitewww.aptose.com↗